Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Short term Debt: 2023-2025

Historic Short term Debt for Spyre Therapeutics (SYRE) over the last 3 years, with Sep 2025 value amounting to $11.0 million.

  • Spyre Therapeutics' Short term Debt fell 55.46% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 55.46%. This contributed to the annual value of $25.1 million for FY2024, which is 1704.32% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Short term Debt stood at $11.0 million, which was down 81.60% from $59.9 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Short term Debt high stood at $164.4 million for Q2 2023, and its period low was $1.4 million during Q4 2023.
  • Over the past 3 years, Spyre Therapeutics' median Short term Debt value was $17.9 million (recorded in 2024), while the average stood at $34.2 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Short term Debt crashed by 98.39% in 2024, and later spiked by 2,168.94% in 2025.
  • Quarterly analysis of 3 years shows Spyre Therapeutics' Short term Debt stood at $1.4 million in 2023, then soared by 1,704.32% to $25.1 million in 2024, then crashed by 55.46% to $11.0 million in 2025.
  • Its Short term Debt stands at $11.0 million for Q3 2025, versus $59.9 million for Q2 2025 and $42.8 million for Q1 2025.